Cardiovascular Medicine

12 pages, 248 KB

Open AccessReview

Mechanisms Involved in the Adverse Cardiovascular Effects of Selective Cyclooxygenase-2 Inhibitors

by Oscar Jesus Leal-Ramos, Luis Felipe Arias-Ruiz, José Miguel Huerta-Velázquez, José Pablo Lamoreaux-Aguayo, Dalton Butcher, Asela Berenice López-Cuellar, Karina Iveth Orozco-Jiménez and Olivia Torres-Bugarín

Cardiovasc. Med. 2025, 28(1), 5; https://doi.org/10.3390/cardiovascmed28010005 - 28 Nov 2025

Viewed by 395

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for managing inflammation, but they are associated with gastrointestinal and renal toxicity upon long-term use. Selective cyclooxygenase-2 (COX-2) inhibitors, or coxibs, were developed to avoid these adverse effects while maintaining anti-inflammatory efficacy. However, accumulating evidence indicates that coxibs may increase the risk of cardiovascular complications. This review explores the pathophysiological mechanisms underlying adverse cardiovascular effects in patients treated with COX-2 inhibitors. These mechanisms include an imbalance between prothrombotic and antithrombotic factors, an altered endocannabinoid metabolism, and downregulation of PPARδ, contributing to thrombosis. Additionally, COX-2 inhibition disrupts renal prostaglandin synthesis, particularly PGE2 and prostacyclins, reduces EP4 receptor expression in macrophages, promotes chemotaxis, and elevates arterial pressure via increased iNOS, ADMA, and L-NMMA activity. At the molecular level, genetic polymorphisms, matrix metalloproteinases, signaling cross-talk, and direct cardiomyocyte injury are implicated. Collectively, these alterations promote a prothrombotic state, fluid retention, enhanced vasoconstriction, impaired vasodilation, myocardial injury, cell death, and cardiac fibrosis. Despite these risks, coxibs are often prescribed without adequate cardiovascular assessment, particularly in patients with pre-existing cardiovascular risk factors. Greater awareness of these mechanisms is essential to optimize the benefit–risk ratio in clinical decision-making involving selective COX-2 inhibitors. Full article

► Show Figures

Graphical abstract

7 pages, 1372 KB

Open AccessCase Report

Double TAVI: What’s Next?

by Ruta Ratyte, Mirjam Löffel and Christoph Ado Kaiser

Cardiovasc. Med. 2025, 28(1), 4; https://doi.org/10.3390/cardiovascmed28010004 - 20 Nov 2025

Viewed by 242

Abstract

Transcatheter aortic valve implantation is rapidly emerging as the leading treatment for severe aortic valve stenosis, especially in elderly and high-risk or inoperable patients. Prosthetic embolism is a rare but serious complication of transcatheter aortic valve replacement. Patients who develop prosthetic embolism are at increased risk of mortality and morbidity. These include stroke and aortic dissection associated with manipulation of the prosthesis in the ascending aorta. Treatment of valve embolisms into the aorta may differ depending on the type of valve; however, it traditionally relies on repositioning the valve to an appropriate position. To date, there are no established pharmaceutical guidelines for the management of patients with valve prosthesis embolization. We present a case report of the implantation of a second aortic valve prosthesis after periprocedural embolization of the first transcatheter valve, resulting in residual floating in the ascending aorta and following treatment with oral anticoagulation as well as single antiplatelet therapy due to the increased risk of thrombogenesis. This case report provides an example of the management of a transcatheter valve embolization with residual floating and highlights the need for further studies to address this issue. Full article

► Show Figures

Figure 1

20 pages, 2302 KB

Open AccessSystematic Review

Global Prevalence of Isolated Systolic, Isolated Diastolic, and Systodiastolic Hypertension: A Systematic Review and Meta-Analysis

by Víctor Juan Vera-Ponce, Lupita Ana Maria Valladolid-Sandoval, Jhosmer Ballena-Caicedo and Fiorella E. Zuzunaga-Montoya

Cardiovasc. Med. 2025, 28(1), 3; https://doi.org/10.3390/cardiovascmed28010003 - 17 Nov 2025

Viewed by 614

Abstract

Arterial hypertension (HTN) is a global public health problem with three distinct subtypes: isolated systolic hypertension (ISH), isolated diastolic hypertension (IDH), and systodiastolic hypertension (SDH), each with unique clinical implications. This systematic review and meta-analysis aimed to determine the global prevalence of ISH, IDH, and SDH and their variability. Following PRISMA guidelines, a search was conducted in SCOPUS, Web of Science, PubMed, and EMBASE. A random-effects model with the Freeman-Tukey transformation was used for the meta-analysis, and a meta-regression was performed to assess temporal trends. Twenty-seven studies from five continents were included, revealing pooled global prevalence rates of 10.72% for ISH, 5.07% for IDH, and 11.71% for SDH. Extreme heterogeneity was observed (I² = 100%), reflecting substantial methodological diversity. The meta-regression suggested an increasing trend for ISH over time, while non-significant decreasing trends were observed for IDH and SDH. In conclusion, all three HTN subtypes show clinically relevant prevalences, with ISH and SDH being nearly twice as common as IDH. The high heterogeneity underscores the urgent need for research standardization, and these findings highlight the importance of differentiating subtypes for more effective population-level screening and public health planning. Full article

► Show Figures

Figure 1

2 pages, 141 KB

Open AccessEditorial

Editor-in-Chief’s Editorial: A New Chapter for Cardiovascular Medicine

by Peter Matt

Cardiovasc. Med. 2025, 28(1), 2; https://doi.org/10.3390/cardiovascmed28010002 - 10 Oct 2025

Viewed by 392

Abstract

It is with great pride and enthusiasm that we announce the relaunch of Cardiovascular Medicine, a journal with a longstanding tradition in the Swiss and international cardiology community [...] Full article

1 pages, 167 KB

Open AccessEditorial

Publisher’s Note: Welcome to the New Home of Cardiovascular Medicine

by Carla Aloè

Cardiovasc. Med. 2025, 28(1), 1; https://doi.org/10.3390/cardiovascmed28010001 - 17 Sep 2025

Viewed by 385

Abstract

Cardiovascular Medicine was launched in 1998 under the title Kardiovaskuläre Medizin, publishing articles in German, French, and English [...] Full article

Journal Menu

Journal Browser

Cardiovasc. Med., Volume 28, Issue 1 (December 2025) – 5 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI